Taro Pharmaceutical, a US based subsidiary of Sun Pharma, will acquire 100 per cent stake in the company.
Sun Pharmaceutical Industries acquired Canada-based Aquinox Pharmaceuticals for $8.2 million through its wholly owned subsidiary Taro Pharmaceutical Industries.
Taro Pharmaceutical, a US based subsidiary of Sun Pharma, will acquire 100 per cent stake in the company.
In a regulatory filing, Sun Pharma said Aquinox Pharmaceuticals is a corporation organised and existing under the laws of the Province of British Columbia that carries on the business of research and development of pharmaceutical products for purposes of their commercialisation.
The company said that the acquisition is likely to be completed by 31 July and no approvals are required for it.
The acquisition comes after the Canadian company’s parent, Aquinox Pharma, merged with Neoleukin Therapeutics Inc in August last year. Prior to the merger with Neoleukin, the parent company was involved in the discovery and development of therapeutics focussed on inflammation, inflammatory pain, and blood cancers.
UK Ministers, Shadow Cabinet leaders, diplomats, business chiefs come together for India Global Forum’s grand Diwali Reception in London Read… Read More
At the India Global Forum’s (IGF) grand Diwali reception in London this week, UK Home Secretary Suella Braverman focussed her message of… Read More
Home Secretary Suella Braverman has said the UK is eager to secure a trade deal with India to boost both… Read More
Chandrasekhar also attended a session on the Future of Digital at the India Global Forum where he spoke on the… Read More
India Global Forum’s glittering awards ceremony with Guest of Honour, UK Chancellor Rishi Sunak, to mark the culmination of a… Read More
The UK government on Wednesday announced 75 fully-funded scholarships for Indian students to study in the UK, beginning September 2022,… Read More
